CDT (CDT Equity) Moat Score: 3/10 (As of Jun. 26, 2026)


CDT CDT Equity Inc CDT
10 GF Score
Price $0.64
! 5 Warning Signs
View Full Analysis

What is CDT Equity Moat Score?

CDT Equity CDT -10.81% 10 Moat Score is 3 as of Jun. 26, 2026. GuruFocus rates CDT with a GF Score™ of 10/100. The stock has 5 warning signs investors should review. Among 1,404 Biotechnology companies, CDT Equity ranks better than 75.5% on this metric.

CDT Equity has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

CDT Equity has No Moat: CDT Equity Inc lacks significant market leadership or unique competitive advantages. It does not exhibit strong network effects, customer switching costs, or proprietary technology. The company has no notable brand strength or regulatory barriers, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes CDT Equity might have No Moat - Very weak/transient advantages.

CDT Equity  (NAS:CDT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

CDT Equity Moat Score Related Terms

CDT vs PULM, ADIL, MBIO: Moat Score Comparison

For the Biotechnology subindustry, CDT Equity's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CDT Equity Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CDT Equity's Moat Score distribution charts can be found below:

* The bar in red indicates where CDT Equity's Moat Score falls into.


CDT
10GF Score
CDT Equity Inc CDT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
CDT Equity (CDT) has a Moat Score of 3 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, CDT Equity ranks #344 out of 1404 companies in the Biotechnology industry, placing it in the top 24.5%.
Is CDT Equity's Moat Score too high?
CDT Equity's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. CDT Equity's value of 3 is 50% above this industry median. Based on the distribution chart, CDT Equity ranks #344 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CDT Equity has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does CDT Equity's Moat Score compare to PULM and ADIL?
According to the Biotechnology industry distribution chart, CDT Equity ranks #344 out of 1404 companies for Moat Score. This places CDT Equity in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. CDT Equity's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CDT Equity's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CDT Equity's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CDT Equity stock overvalued right now?
CDT Equity (CDT) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. CDT Equity's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For CDT Equity (CDT), the current Moat Score is 3 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CDT Equity Business Description

Address 4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
10GF Score

Get the complete analysis for CDT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.64
Price